R D productivity

Conference Meeting Boosting R D Productivity. The Smart Pharma Eorum S" October 2002. 

The environment for pharmaceutical R D is changing, with the main challenge stemming from decreasing R D productivity. R D costs are increas-... 

Ultimately, software is bought to accomplish a business result. Therefore, software offerings in pharmaceutical R D ought to somehow accelerate R D productivity, or at least give cost savings along the pipeline. Yet the reality is that most scientific software is not sold on the basis of delivering... 

In this respect, current state-of-the-art ends up in a draw. This book makes a substantial contribution to the current literature on the analytics of polymer additives, follows up an earlier industrial tradition and lays a foundation for the future. It will be of great value to a broad readership comprising industrial and academic (analytical) chemists, polymer scientists and physicists, technologists and engineers, and other professionals involved in R D, production, use and reuse of polymers and additives in all areas of application, including manufacturers, formulators, compounders, end users, government legislators and their staff, forensic scientists, etc. 

The purpose of this monograph, the first to be dedicated exclusively to the analytics of additives in polymers, is to evaluate critically the extensive problemsolving experience in the polymer industry. Although this book is not intended to be a treatise on modem analytical tools in general or on polymer analysis en large, an outline of the principles and characteristics of relevant instrumental techniques (without hands-on details) was deemed necessary to clarify the current state-of-the-art of the analysis of additives in polymers and to accustom the reader to the unavoidable professional nomenclature. The book, which provides an in-depth overview of additive analysis by focusing on a wide array of applications in R D, production, quality control and technical service, reflects the recent explosive development of the field. Rather than being a compendium, cookery book or laboratory manual for qualitative and/or quantitative analysis of specific additives in a variety of commercial polymers, with no limits to impractical academic exoticism (analysis for its own sake), the book focuses on the fundamental characteristics of the arsenal of techniques utilised industrially in direct relation... 

How to improve R D productivity the pharmaceutical industry s grand challenge. Nat Rev Drug Discov 9 203-214... 

If sponsors had perfect information, it would be easy to set rewards. McGuire has shown that the optimum reward is, in principle, solvable as a utility maximization problem (McGuire 2003 Institute of Medicine 2004). However, McGuire s proof assumes that the R D production function is known to second order. In fact, the values (and even the sign) of these coefficients are very uncertain and depend on information that is not public knowledge (Sloan and Easley, Chapter 6). ... 

Institutes ECN,TNO R D, production, components, modelling, systems, strategic infra-structural studies. 

More than 1000 companies worldwide are involved in fine-chemical R D, production, and sales. Only a minority have been founded with the specific... 

Possible root causes for the slump in pharma R D productivity are discussed in Section 15.2. 

D. Aboody and B. Lev, R D Productivity in the Chemical Industry, New York University, Stern School of Business, 2001. 

A joint venture (J V) allows a combination of tangible and intangible assets of the partners in a way to optimize the combined offering. JVs are popular in the chemical industry, particularly between Western and Chinese companies in China. It has to be pointed out, however, that the of JV failure rate is quite high. This is particularly the case for horizontal JVs, where all activities, such as R D, production, and M S, are shared. The main reasons are culture clashes that prevent the expected synergies and conflicts of interests with other activities of the partners. 

The first two entries listed in the table, namely, Obsolescence of the big pharma business model and Slump in R D productivity, are of particular relevance to the fine-chemical industry and are dealt with in more detail in the following two sections. They impact the outsourcing policy and consequently the demand for new PFCs. 

R D Productivity, Hughes Aircraft Co., Culver City, Calif., 1978. 

Cross-functional. Commonly used as project teams to develop and launch new products where integration of R D, Production and Marketing functions are required. They are designed to overcome the vertical barriers that develop between functions. 

---